Essential thrombocythemia after treatment of non-Hodgkin's lymphoma.
Maciel
James Farley Rafael
JF
de Lourdes Chauffaille
Maria
M
Inaoka
Riguel Jun
RJ
Colleoni
Gisele Wally Braga
GW
Yamamoto
Mihoko
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000139:chemically induced*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone